Sign in
Subscribe
    • Stock Lists
      arrow_drop_down
      • Longevity Stocks
      • COVID-19 Stocks
    • Longevity Trial Tracker
    • Newsletter
    • Resources
      arrow_drop_down
      • Events
      • Supporters
    • About
    Subscribe

    Recursion Pharmaceuticals

    AI/ML cell imaging for drug discovery. Senolytics.

    • Profile
    • prev
    • next
    • Bookmark
    • Website
    • Share
    • prev
    • next
    $RXRX
    $8.82
    $0.2900
    -3.13%

    Marketcap: $1.67B
    Volume: 307.18K

    Recursion Pharmaceuticals, Inc.
    Symbol: RXRX
    Employees: 400
    Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
    Website https://www.recursion.com

    LongevityMarketcap.com 2021.

      • Facebook
      • Twitter
      • WhatsApp
      • Telegram
      • LinkedIn
      • Tumblr
      • VKontakte
      • Mail
      • Copy link